Triple Chemotherapy Makes a Difference in Biliary Tract Cancer Treatment

Nab-paclitaxel (Abraxane) , an albumin-bound nanoparticle chemotherapy product, added to gemcitabine-cisplatin, may markedly prolong survival in advanced biliary tract cancer compared with gemcitabine-cisplatin alone. Results published on 18 April in JAMA Oncologydemonstrated this in a phase 2 clinical trial.
For advanced biliary tract cancer (cholangiocancer) , the standard treatment is gemcitabine and cisplatin doublet therapy, with overall survival below 1 year. Although biliary tract cancers are rarer than other cancers, approximately 130 thousand new cases are estimated worldwide annually. Outcomes are generally poor, and diagnosis usually occurs at advanced stages.
In this study involving 60 patients, adding nab-paclitaxel to gemcitabine + cisplatin produced progression-free survival of 11.8 months and overall survival of 19.2 months.
Historically, advanced biliary tract cancer patients receiving standard treatment have had median progression-free survival of 8 months and median overall survival of 11,7 months.
Gemcitabine and cisplatin have formed the backbone of newly diagnosed advanced biliary tract cancer treatment for approximately 9 years, and no phase 3 randomized trial has yet shown superiority over them.

Of 60 patients, 38 (% 63) had intrahepatic cholangiocarcinoma, nine (% 15) extrahepatic cholangiocarcinoma, and 13 (% 22) gallbladder cancer. In %78 of patients, disease was metastatic, while %22 had locally advanced cancer. Average age was 58,4.
This open-label, single-arm clinical trial was conducted at the University of Texas MD Anderson Cancer Center and the Mayo Clinic in Arizona.
Study Details and Noteworthy Findings
- Initially, patients received treatment over 21-day periods on days 1 and 8: gemcitabine (1000 mg / m2), cisplatin (25 mg / m2) and nab-paclitaxel (125 mg / m2). However, because the first 32 patients experienced hematological side effects, doses in 28 patients were reduced to 800, 25 and 100 mg / m2, respectively.
- The partial response rate was % 45 and disease control rate % 84.
- Severe (grade 3 or higher) side effects occurred in % 58 of patients, and nine patients (% 16) withdrew from the study. Neutropeniaoccurred in 19 patients (% 33) and was the most common severe side effect.
- Shroff, one of the study authors, said the most severe side effects occurred among those receiving the original high doses, and lower doses were being used in the phase III study that began in February 2019.
- Of these 60 patients whose biliary tract tumors were unresectable at diagnosis, 12 were also reported to have become resectable (removable by surgery). They left the study because they could undergo surgery, rather than because of side effects or cancer progression.
The finding that % 20 of patients became operable after this triple chemotherapy was described by researchers as a fantastic finding .
Shroff said the additional months of survival suggested by early results were invaluable to patients, adding: “We had patients in this study looking toward milestones, trying to make it to their daughters’ weddings or grandchildren’s births. The impact of an extra 8 months is profound.”
Researchers explained that their reason for testing nab-paclitaxel in biliary tract cancer involved a dense tumor microenvironment characteristic of pancreatic cancer, in which nab-paclitaxel is effective. Nab-paclitaxel appears to weaken the tumor microenvironment.
In conclusion, although this phase 2 study is small and lacks a control group and random patient selection, the survival difference is quite marked compared with historical data. This raises hopes for the newly initiated phase 3 study.
Sources
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers A Phase 2 Clinical Trial.
JAMA Oncology, 18 April 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.